Evidence map›Paper›PMID 38725003›Full record

ArticleWorld journal of surgical oncology2024

Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer.

Wei Chen, Jing Zhang, Fenxiang Li, Zongshun Chen, Junjie Li, Da-Lin Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei Chen *Breast Surgery Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China, No. 55, Section 4, Renmin South Road, Sichuan.
Jing Zhang *Department of Epidemiology, School of Medicine, Jinan University, Guangzhou, China, No. 601, Huangpu Avenue West, Tianhe District, 510632.
Fenxiang LiDepartment of Epidemiology, School of Medicine, Jinan University, Guangzhou, China, No. 601, Huangpu Avenue West, Tianhe District, 510632.
Zongshun ChenBreast Surgery Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China, No. 55, Section 4, Renmin South Road, Sichuan.
Junjie LiBreast Surgery Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China, No. 55, Section 4, Renmin South Road, Sichuan. lijunjie@scszlyy.org.cn.ORCID http://orcid.org/0000-0003-4510-8261
Da-Lin LuDepartment of Epidemiology, School of Medicine, Jinan University, Guangzhou, China, No. 601, Huangpu Avenue West, Tianhe District, 510632. ludalin999@163.com.ORCID http://orcid.org/0000-0002-6896-6835

Funding

National Natural Science Foundation of China 82003522Natural Science Foundation of Sichuan Province 2023NSFSC0548Wu Jieping Medical Foundation 320.6750.2023-18-99
6 · The paper itself

Abstract

purposeThis study investigated the changes in the fasting blood glucose (FBG), fasting triglyceride (FTG), and fasting total cholesterol (FTC) levels during neoadjuvant therapy (NAT) for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and the association with pathologic complete response (pCR).

methodsRelevant data from Sichuan Cancer Hospital from June 2019 to June 2022 were collected and analyzed, and FBG, FTG, and FTC were divided into baseline, change, and process groups, which were grouped to analyze the changes after receiving NAT and the association with pCR.

resultsIn the estrogen receptor (ER)-negative subgroup, patients with low levels of FTG in the process group were more likely to achieve pCR compared to high levels, and in the progesterone receptor (PR)-negative subgroup, patients with lower FTG compared to higher FTG after receiving NAT was more likely to achieve pCR.

conclusionsPatients with HER2-positive BC undergoing NAT develop varying degrees of abnormalities (elevated or decreased) in FBG, FTG, and FTC; moreover, the status of FTG levels during NAT may predict pCR in ER-negative or PR-negative HER2-positive BC.Early monitoring and timely intervention for FTG abnormalities may enable this subset of patients to increase the likelihood of obtaining a pCR along with management of abnormal markers.

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlood GlucoseCholesterolFemaleFollow-Up StudiesHumansMiddle AgedPathologic Complete ResponsePrognosisReceptors, EstrogenBiomarkers, TumorBlood GlucoseCholesterolERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneTriglyceridesBiochemical markersGlycemic and lipid managementHER2-positive breast cancer, Neoadjuvant therapyPredicting pathologic complete response

Identifiers

PMID38725003
PMCPMC11080081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.